Categories
Tags
Authors: Bryant A, Lawrie TA, Dowswell T, Fordham E, Mitchell S, Hill SR et al. PMID: 34145166 PMCID: PMC8248252 DOI: 10.1097/MJT.0000000000001402 Abstract Background: Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty: We assessed the [...]
Categories: I-CARE Early Covid, MATH+
Tags: COVID-19, ivermectin
Authors: Ahmadi R, Salari S, Reihani H, Eslami S. PMID: PMC8358331 DOI: 10.1002/fsn3.2226 Abstract Background: Curcumin, a natural polyphenolic compound, is proposed as a potential treatment option for patients with coronavirus disease by inhibiting the entry of virus to the cell, encapsulation of the virus and viral protease, as well as modulating various cellular signaling [...]
Categories: I-CARE Early Covid, I-PREVENT, I-RECOVER Post-Vaccine
Authors: Duarte M, Pelorosso F, Nicolosi L, Salgado V, Vetulli H PMID: 34189447 PMCID: PMC8225700 DOI: 10.1016/j.eclinm.2021.100962 Abstract Background: Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. Methods: This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:1 allocation ratio. Participants included patients from 18 [...]
Categories: I-CARE Early Covid, MATH+
Tags: COVID-19, telmisartan
Authors: Lopes RD, Furtado RH, Bronhara B, Damiani LP, Barbosa LM. DOI:https://doi.org/10.1016/S0140-6736(21)01203-4 Abstract Background COVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised with COVID-19 is unknown. We aimed to compare the efficacy and safety of therapeutic versus prophylactic anticoagulation in this population. Methods [...]
Categories: MATH+
Tags: Anticoagulant, COVID-19
Authors: Menendez-Arias L PMID: 34118236 PMCID: PMC8188802 DOI: 10.1016/j.jbc.2021.100867 Abstract Molnupiravir, a prodrug of the nucleoside derivative β-D-N4-hydroxycytidine (NHC), is currently in clinical trials for COVID-19 therapy. However, the biochemical mechanisms involved in molnupiravir-induced mutagenesis had not been explored. In a recent study, Gordon et al. demonstrated that NHC can be incorporated into viral RNA [...]
Categories: I-CARE Early Covid
Tags: COVID-19, molnupiravir, SARS-CoV-2
Authors: DiPierro F, Derosa G, Maffioli P, Togni S, Riva A PMID: 34135619 PMCID: PMC8197660 DOI: 10.2147/IJGM.S318720 Abstract Background: Quercetin, a well-known naturally occurring polyphenol, has recently been shown by molecular docking, in vitro and in vivo studies to be a possible anti-COVID-19 candidate. Quercetin has strong antioxidant, anti-inflammatory, immunomodulatory, and antiviral properties, and it [...]
Categories: I-RECOVER Post-Vaccine
Authors: Cuesta-Llavona E, Gomez J, Albaiceta GM, Amado-Rodriguez L, Garcia-Clemente M PMID: 34116286 PMCID: PMC8169316 DOI: 10.1016/j.intimp.2021.107825 Abstract The chemokine receptor CCR5 has been implicated in COVID-19. CCR5 and its ligands are overexpressed in patients. The pharmacological targeting of CCR5 would improve the COVID-19 severity. We sought to investigate the role of the CCR5-Δ32 variant [...]
Categories: I-RECOVER Long Covid
Authors: Pont G, Pastorino L, Manfredini M, Ozben T, Oliva G, Kaleci S PMID: 34061414 PMCID: PMC8209953 DOI: 10.1002/jcla.23798 Abstract Background: Homocysteine assessment has been proposed as a potential predictive biomarker for the severity of COVID-19 infection. The purpose of this review was to analyze the correlation between the prevalence of MTHFR C677 T gene [...]
Categories: I-RECOVER Post-Vaccine
Authors: Jamme M, Mazeraud A PMID: 33769769 DOI: 10.1097/CCM.0000000000004926 Abstract We have read with a great interest the study by Fernandez et al (1) published in a recent issue of Critical Care Medicine. In this case-series, the authors reported the outcome of four patients admitted in ICU with coronavirus disease 2019 (COVID-19) complicated with multiorgan [...]
Categories: I-RECOVER Post-Vaccine
Tags: COVID-19, Plasmapheresis
Authors: Chen T, Song J, Liu H, Zheng H, Chen C PMID: 34035353 PMCID: PMC8149409 DOI: 10.1038/s41598-021-90351-y Abstract The objective of this study was to detect the Epstein-Barr virus (EBV) coinfection in coronavirus disease 2019 (COVID-19). In this retrospective single-center study, we included 67 COVID-19 patients with onset time within 2 weeks in Renmin Hospital [...]
Categories: I-RECOVER Post-Vaccine
Tags: COVID-19


